CoChat

Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients

Open access
Karavasilis, Vasilios, Seddon, Beatrice M., Ashley, Susan, Al‐Muderis, Omar, Fisher, Cyril, Judson, Ian · 2008 · Cancer
Cited by 214

The DOI matches its Crossref record.

Abstract

BACKGROUND.: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft‐tissue sarcomas (STS) treated on routine palliative protocols. METHODS.: Patients with STS who had first‐line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database. Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study. RESULTS.: In all, 488 patients (242 male, 246 female) fulfilled the study criteria. The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease. The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%). In all, 61% received single‐agent chemotherapy, usually doxorubicin. An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived ‘clinical benefit’ (objective responses + stable disease for ≥6 months). Median duration of response was 9 months and median posttreatment overall survival (OS) was 12 months. In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors. Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent. CONCLUSIONS.: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS. Synovial sarcoma and liposarcoma subtypes have a better prognosis. However, the overall poor outcome of these patients indicates the need to continue the search for more effective agents. Cancer 2008. © 2008 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.23332

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 214

Metadata

Authors
Karavasilis, V., Seddon, B. M., Ashley, S., Al‐Muderis, O., Fisher, C., & Judson, I.
Venue
Cancer
Publisher
Wiley
Published
2008-03-19
Volume
112
Issue
7
Pages
1585-1591
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2032646205
Cited by
214
References
0
FWCI
9.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. https://app.cochat.ai/papers/10.1002/cncr.23332
The paper
Karavasilis, V., Seddon, B. M., Ashley, S., Al‐Muderis, O., Fisher, C., & Judson, I. (2008). Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. Cancer. https://doi.org/10.1002/cncr.23332

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.